Pharming vs Rhythm Pharmaceuticals
PHAR and RYTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHAR and RYTM compare
Rhythm Pharmaceuticals grew revenue faster over the last twelve months (53.5% versus 26.6% for Pharming).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −85.6% at Rhythm Pharmaceuticals.
Pharming scores higher on the StockData Score (8 against 5 for Rhythm Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHAR | RYTM |
|---|---|---|
| Size and price | ||
| Market cap | – | $7.7B |
| Share price | $13.40 | $112.16 |
| Change, 1 year | −23.6% | 14.9% |
| Change, 5 years | 55.5% | 989% |
| Beta (5Y) | 0.56 | 1.41 |
| Employees | 50K | 414 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 32.2× |
| P/B | – | 75.0× |
| Fair value | – | $31.38 |
| Margin of safety | – | −257% |
| Growth | ||
| Revenue growth (TTM) | 26.6% | 53.5% (better) |
| Revenue growth, 5Y average | 12.1% | – |
| EPS growth, 5Y average | −40.8% | – |
| Profitability | ||
| Gross margin | 87.9% | 89.0% (better) |
| Operating margin | 6.9% (better) | −83.6% |
| Net margin | 0.76% (better) | −85.6% |
| FCF margin | 14.3% | – |
| Return on equity | – | −451% |
| Financial health | ||
| Debt / equity | – | 1.03 |
| Interest coverage | 132× (better) | −10.9× |
| Current ratio | 2.59 | 3.45 (better) |
| Altman Z-score | – | 16.27 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.32% | 112% |
| Held by insiders | 0.00% | 1.1% |
| Insider net buying, 12 months | – | −$36.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 17.1% |
Go deeper
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
- RYTM stock overview
- RYTM income statement
- RYTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.